When Lamotrigine Monotherapy Has Not Achieved Seizure Freedom in Childhood Absence Epilepsy with Absence Seizures Only

This protocol addresses children with childhood absence epilepsy (CAE) whose seizure pattern is limited exclusively to absence seizures, with no history of generalised tonic-clonic seizures — and in whom lamotrigine (LTG) monotherapy has not achieved adequate seizure control.

Previous Treatment & Escalation Trigger

The preceding treatment step used lamotrigine (LTG) monotherapy, titrated to a target serum level of 5–15 µg/mL. This protocol is indicated when that approach failed to reach the primary goal: complete freedom from absence seizures.

Clinical Goal

Complete freedom from absence seizures.

Next-Step Approach — Partial Overview

After lamotrigine monotherapy failure, the evidence-based next step involves either a specific combination antiepileptic regimen or a distinct alternative single-agent approach.

The full protocol — agents, sequencing, and clinical decision points — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

The treatment of choice for CAE with absence seizures only is ethosuximide.

Therefore, based on the CAE trial, ETX is the drug of choice as initial monotherapy for CAE, when absence seizures are the only seizure type, but there are specific treatment considerations for each drug, which are discussed below.

Persistent seizures or AE on ETX, VPA and LTG monotherapy: Treat with combination of VPA and LTG, or consider clobazam.

We recommend trying a combination of VPA and LTG.

Because VPA inhibits LTG metabolism, initiation of LTG when a patient is already on VPA begins at a lower dose, increases in smaller increments, and reaches a lower target dose than dosing in the absence of VPA.

If LTG is not efficacious or only partly efficacious at this point, the next treatment to consider is clobazam.

View source ↗